ORAMED PHARMACEUTICALS INC.
oramedpharmaceuticals.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Oramed shows severe cash burn with cash declining 71% from $45.9M to $13.2M in just three months, indicating a potential liquidity crisis. Despite positive investment gains reducing accumulated deficit by $38.3M, the company faces material going concern risks given the rapid cash depletion rate.
Red Flags Detected (5)
Cash and cash equivalents plummeted 71% from $45.9M to $13.2M in Q1 2026
Total current assets declined 49% from $133.3M to $68.2M
At current burn rate, cash runway appears critically short
2 more red flags detected
Key Takeaways
Company burned through over $32M in cash in just three months
Investment portfolio gains of $38.3M helped reduce accumulated losses but don't address liquidity crisis
1 more takeaway
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.